HSBC turns more bullish on Amgen (AMGN) into 2026
I'm PortAI, I can summarize articles.
HSBC has increased its price target for Amgen Inc. (NASDAQ:AMGN) from $381 to $425, maintaining a Buy rating. This adjustment is part of HSBC's 2026 outlook for the pharmaceutical sector, where Amgen is highlighted as one of the 12 Best Dogs of the Dow to invest in.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments